Documentos de Steg P.G. | REDI

Regresar

Mostrando 3 resultados de: 3

Filtros aplicados

Objetivos de Desarrollo Sostenible: "ODS 9: Industria, innovación e infraestructura"

Subtipo de publicación

Publisher

European Heart Journal - Cardiovascular Pharmacotherapy(1)

Área temáticas

Enfermedades(3)

Farmacología y terapéutica(3)

Cirugía y especialidades médicas afines(1)

Fisiología humana(1)

Medicina y salud(1)

Área de conocimiento

Enfermedad cardiovascular(3)

Medicina interna(3)

Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar(3)

ODS 17: Alianzas para lograr los objetivos(2)

ODS 10: Reducción de las desigualdades(1)

Año de Publicación

Origen

Palabras Claves

acute coronary syndrome(2)

Coronary artery disease(1)

Heart Disease Risk Factors(1)

PCSK9 inhibitors(1)

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Abstract: Background: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB

Palabras claves:

acute coronary syndrome, apolipoproteins B, cholesterol, LDL, Heart Disease Risk Factors, PCSK9 inhibitors

Aylward P.E., Bhatt D.L., Bittner V.A., Danchin N., Diaz R., Dilic M., Drexel H., Edelberg J.M., Goodman S.G., Gotcheva N.N., Hagström E., Hanotin C., Harrington R.A., Jukema J.W., Lecorps G., Liberopoulos E., Lopes R.D., Mahaffey K.W., Manvelian G., Marx N., McGinniss J., Moryusef A., Ostadal P., PATRICIO LOPEZ -JARAMILLO, Pecin I., Pordy R., Poulsen S.H., Prieto J.C., Reiner Z., Roe M.T., Sasiela W.J., Scemama M., Schwartz G.G., Sinnaeve P.R., Steg P.G., Szarek M., Tamby J.F., Tricoci P., Viigimaa M., White H.D., Yong H., Zeiher A.M.

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

Abstract: Background: The 2018 US cholesterol management guidelines recommend additional lipid-lowering therap

Palabras claves:

acute coronary syndrome, alirocumab, dyslipidemias, GUIDELINE

Baccara-Dinet M.T., Bhatt D.L., Bittner V.A., DIaz R., Goodman S.G., Harrington R.A., Jukema J.W., Li Q.H., Lopes R.D., Louie M.J., Moriarty P.M., PATRICIO LOPEZ -JARAMILLO, Roe M.T., Schwartz G.G., Steg P.G., Szarek M., Vogel R., White H.D., Zeiher A.M.

Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial

Abstract: Aims: To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheral

Palabras claves:

aspirin, Coronary artery disease, Peripheral artery disease, rivaroxaban

Aboyans V., Alings M., Anand S.S., Avezum A.J., Bangdiwala S.I., Bhatt D.L., Bosch J.J., Branch K.R.H., Camillo Felix, Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.L., DIaz R., Eikelboom J.W., Ertl G., Fox K.A.A., Guzik T.J., Hori M., Ibrahim K.S., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Lopez-Jaramillo P., Maggioni A.P., Metsarinne K.P., Muehlhofer E., Neumann C., O’Donnell M., Parkhomenko A.N., Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Stoerk S., Tasto C., Tonkin A.M., Torp-Pedersen C., Tyrwitt J., Vanassche T., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yusuf S., Zhu J.